Cancer Detection and Diagnosis Research in Nebraska
Cancer Detection and Diagnosis Research (93.394) awarded $8.7 million to recipients in Nebraska in 6 grants from fiscal 2021 to 2025, 0.3% of the program's national total. Board of Regents of the University of Nebraska received the most, $8.6 million.
- Awarded in Nebraska$8.7 million
- Awards6
- Share of the program0.3%
- Rank among states32nd of 45
- National total$2.7 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 4 | $2.9 million |
| FY 2022 | 4 | $2.2 million |
| FY 2023 | 2 | $1.1 million |
| FY 2024 | 3 | $1.2 million |
| FY 2025 | 3 | $1.3 million |
Recipients in Nebraska
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| Board of Regents of the University of Nebraska | Colleges and universities | 5 | $8.6 million |
| CHN Nebraska | Nonprofits | 1 | $282,813 |
Open opportunities under this program
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
- Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
See all 47 on the program page
Questions people ask
How much Cancer Detection and Diagnosis Research money goes to Nebraska?
$8.7 million from fiscal 2021 to 2025, across 6 awards. Nebraska ranks 32nd of 45 states and territories for this program.
Who receives Cancer Detection and Diagnosis Research money in Nebraska?
The largest recipient is Board of Regents of the University of Nebraska, with $8.6 million in 5 awards. Next is CHN Nebraska.
Can organizations in Nebraska apply now?
Yes, 47 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cancer Detection and Diagnosis Research in other states
Other large programs in Nebraska
- Grants to States for Medicaid
- Highway Planning and Construction
- Education Stabilization Fund
- National School Lunch Program
- Disaster Grants - Public Assistance (Presidentially Declared Disasters)
- Child Care and Development Block Grant
- Children's Health Insurance Program
- Special Education Grants to States
- Broadband Equity, Access, and Deployment Program
- Greenhouse Gas Reduction Fund: Clean Communities Investment Accelerator